米氮平和丁螺环酮治疗广泛性焦虑症的对照研究

A comparative study between mirtazapine and buspirone in the treatment of generalized anxiety disorder

目的:比较米氮平与丁螺环酮治疗广泛性焦虑症的疗效及不良反应。方法:将符合CCMD-III诊断标准的64例广泛性焦虑症患者随机分为两组,分别服米氮平或丁螺环酮治疗6周,于疗前和疗后第6周末进行汉密尔顿焦虑量表(HAMA)、焦虑自评量表(SAS)、临床疗效总评(CG I-SI)和副反应量表(TESS)评定疗效和不良反应。结果:米氮平和丁螺环酮疗效相仿,但躯体焦虑因子分有显著性差异。两组不良反应均轻而易耐受。结论:米氮平是治疗广泛性焦虑症的安全有效药物,更适用于伴重性抑郁的广泛性焦虑症。

Objective：To evaluate the efficacy and side effects of mirtazapine and buspirone in the treatment of generalized anxiety disorder. Methods：Sixty - four patients with generalized anxiety disorder met the criteria of CCMD -Ⅲ were randomly assigned to receive mirtazapine （ n = 34 ） or buspirone （ n = 30 ）. HAMA, SAS, CGI - SI and TESS were adopted to evaluate the efficacy and side effects before and after six weeks of the treatment. Results： The efficacy of mirtazapine and buspirone had no significant difference, but mirtazapine was better than buspirone in the treatment of physical anxiety patient. They had slighter side effects. Conclusions：Mirtazapine is a safe and effective drug in the treatment of generalized anxiety disorder, suiting for generalized anxiety disorder with major depression.